BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25873370)

  • 1. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.
    Kumar NB; Pow-Sang J; Egan KM; Spiess PE; Dickinson S; Salup R; Helal M; McLarty J; Williams CR; Schreiber F; Parnes HL; Sebti S; Kazi A; Kang L; Quinn G; Smith T; Yue B; Diaz K; Chornokur G; Crocker T; Schell MJ
    Cancer Prev Res (Phila); 2015 Oct; 8(10):879-87. PubMed ID: 25873370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.
    Kumar NB; Pow-Sang J; Spiess PE; Park J; Salup R; Williams CR; Parnes H; Schell MJ
    Oncotarget; 2016 Oct; 7(43):70794-70802. PubMed ID: 28053292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
    Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
    Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.
    Bettuzzi S; Brausi M; Rizzi F; Castagnetti G; Peracchia G; Corti A
    Cancer Res; 2006 Jan; 66(2):1234-40. PubMed ID: 16424063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Green tea catechins for chemoprevention of prostate cancer in patients with histologically-proven HG-PIN or ASAP. Concise review and meta-analysis.
    Perletti G; Magri V; Vral A; Stamatiou K; Trinchieri A
    Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of green tea catechins in patients with high-grade prostatic intraepithelial neoplasia: Results of a short-term double-blind placebo controlled phase II clinical trial.
    Micali S; Territo A; Pirola GM; Ferrari N; Sighinolfi MC; Martorana E; Navarra M; Bianchi G
    Arch Ital Urol Androl; 2017 Oct; 89(3):197-202. PubMed ID: 28969404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.
    Marshall JR; Tangen CM; Sakr WA; Wood DP; Berry DL; Klein EA; Lippman SM; Parnes HL; Alberts DS; Jarrard DF; Lee WR; Gaziano JM; Crawford ED; Ely B; Ray M; Davis W; Minasian LM; Thompson IM
    Cancer Prev Res (Phila); 2011 Nov; 4(11):1761-9. PubMed ID: 21896650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer.
    Lane JA; Er V; Avery KNL; Horwood J; Cantwell M; Caro GP; Crozier A; Smith GD; Donovan JL; Down L; Hamdy FC; Gillatt D; Holly J; Macefield R; Moody H; Neal DE; Walsh E; Martin RM; Metcalfe C
    Cancer Prev Res (Phila); 2018 Nov; 11(11):687-696. PubMed ID: 30309839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.
    Nguyen MM; Ahmann FR; Nagle RB; Hsu CH; Tangrea JA; Parnes HL; Sokoloff MH; Gretzer MB; Chow HH
    Cancer Prev Res (Phila); 2012 Feb; 5(2):290-8. PubMed ID: 22044694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.
    Garcia FA; Cornelison T; Nuño T; Greenspan DL; Byron JW; Hsu CH; Alberts DS; Chow HH
    Gynecol Oncol; 2014 Feb; 132(2):377-82. PubMed ID: 24388920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
    Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
    Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.
    Kumar NB; Patel R; Pow-Sang J; Spiess PE; Salup R; Williams CR; Schell MJ
    Oncotarget; 2017 Nov; 8(58):99093-99103. PubMed ID: 29228755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
    Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
    J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.
    Chow HH; Hakim IA; Vining DR; Crowell JA; Ranger-Moore J; Chew WM; Celaya CA; Rodney SR; Hara Y; Alberts DS
    Clin Cancer Res; 2005 Jun; 11(12):4627-33. PubMed ID: 15958649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
    Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
    J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial.
    Price D; Stein B; Sieber P; Tutrone R; Bailen J; Goluboff E; Burzon D; Bostwick D; Steiner M
    J Urol; 2006 Sep; 176(3):965-70; discussion 970-1. PubMed ID: 16890670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of high grade prostatic intraepithelial neoplasia and atypical small acinar proliferation in the contemporary era.
    Moore CK; Karikehalli S; Nazeer T; Fisher HA; Kaufman RP; Mian BM
    J Urol; 2005 Jan; 173(1):70-2. PubMed ID: 15592031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate adenocarcinoma detected after high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation.
    López JI
    BJU Int; 2007 Dec; 100(6):1272-6. PubMed ID: 17850386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The presence of high-grade prostatic intraepithelial neoplasia or atypia on prostate biopsy does not adversely affect prostatectomy outcomes for patients otherwise eligible for active surveillance.
    Pietzak EJ; Kabarriti AE; Mucksavage P; Bavaria T; Van Arsdalen K; Malkowicz SB; Wein AJ; Guzzo TJ
    Urology; 2014 Dec; 84(6):1442-7. PubMed ID: 25288572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies.
    Scattoni V; Roscigno M; Freschi M; Dehò F; Raber M; Briganti A; Fantini G; Nava L; Montorsi F; Rigatti P
    Arch Ital Urol Androl; 2005 Mar; 77(1):31-6. PubMed ID: 15906787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.